Rational targeting of peroxisome proliferating activated receptor subtypes

Current Medicinal Chemistry

Volumn 18, Issue 36, 2011, Pages 5598-5623

  Nevin, D K ^a   Lloyd, D G ^a   Fayne, D ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Dual PPAR Modulator; Nuclear Receptor; Pan PPAR Modulator; Partial PPAR Modulator; Peroxisome Proliferating Activated Receptor (PPAR); PPAR Modulator; PPAR Modulator; PPAR Modulator; Rational Drug Discovery; Selective PPAR Modulators (SPPARMs); Virtual Screening

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; BALAGLITAZONE; BEZAFIBRATE; BMS 687453; CIGLITAZONE; CLOFIBRATE; FARGLITAZAR; FIBRIC ACID DERIVATIVE; GW 0072; GW 2331; GW 693085; ISOGLITAZONE; KD 3010; MBX 8025; METAGLIDASEN; MURAGLITAZAR; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; SB 213068; SB 236636; SODELGLITAZAR; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CARCINOGENESIS; CHEMICAL INTERACTION; COMPUTER PROGRAM; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HEART MUSCLE CELL; HUMAN; HYDROGEN BOND; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IC 50; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIGAND BINDING; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRTUAL DRUG SCREENING; WEIGHT GAIN; XENOPUS LAEVIS;

EID: 84055183812     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798347243     Document Type: Article

References (136)

1. http://cardiobrief.org/2011/06/09/pioglitazone-actos-suspended-in- franceover-cancer-concerns (accessed September 16, 2011).
2. Kletzien, R. F.; Clarke, S. D.; Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992, 41 (2), 393-8.
3. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97 (2), 161-3.
4. Zieleniak, A.; Wojcik, M.; Wozniak, L. A., Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz) 2008, 56 (5), 331-45.
5. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R., The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43 (4), 527-50. (Pubitemid 30127149)
6. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W., Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68 (5), 879-87.
7. Schmidt, A.; Endo, N.; Rutledge, S. J.; Vogel, R.; Shinar, D.; Rodan, G. A., Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992, 6 (10), 1634-41.
8. Kliewer, S. A.; Forman, B. M.; Blumberg, B.; Ong, E. S.; Borgmeyer, U.; Mangelsdorf, D. J.; Umesono, K.; Evans, R. M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994, 91 (15), 7355-9. (Pubitemid 24226862)
9. Chen, F.; Law, S. W.; O'Malley, B. W., Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun 1993, 196 (2), 671-7. (Pubitemid 23337660)
10. Amri, E. Z.; Bonino, F.; Ailhaud, G.; Abumrad, N. A.; Grimaldi, P. A., Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J Biol Chem 1995, 270 (5), 2367-71.
11. Nahle, Z., PPAR trilogy from metabolism to cancer. Curr Opin Clin Nutr Metab Care 2004, 7 (4), 397-402. (Pubitemid 40340645)
12. Barish, G. D.; Narkar, V. A.; Evans, R. M., PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116 (3), 590-7. (Pubitemid 43326863)
13. Escher, P.; Braissant, O.; Basu-Modak, S.; Michalik, L.; Wahli, W.; Desvergne, B., Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001, 142 (10), 4195-202. (Pubitemid 32907045)
14. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K.; Lefebvre, A. M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J. C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M. R.; Staels, B.; Vidal, H.; Auwerx, J., The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272 (30), 18779-89. (Pubitemid 27318225)
15. Mukherjee, R.; Jow, L.; Croston, G. E.; Paterniti, J. R., Jr., Identification, characterization, and tissue distribution of human peroxisome proliferatoractivated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272 (12), 8071-6. (Pubitemid 27137374)
16. Fajas, L.; Fruchart, J. C.; Auwerx, J., PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998, 438 (1-2), 55-60. (Pubitemid 28517834)
17. Ricote, M.; Huang, J.; Fajas, L.; Li, A.; Welch, J.; Najib, J.; Witztum, J. L.; Auwerx, J.; Palinski, W.; Glass, C. K., Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998, 95 (13), 7614-9.
18. Wu, Z.; Bucher, N. L.; Farmer, S. R., Induction of peroxisome proliferatoractivated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol 1996, 16 (8), 4128-36. (Pubitemid 26251212)
19. Kersten, S.; Desvergne, B.; Wahli, W., Roles of PPARs in health and disease. Nature 2000, 405 (6785), 421-4. (Pubitemid 30367411)
20. Bernardo, A.; Minghetti, L., PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 2006, 12 (1), 93-109.
21. Kapadia, R.; Yi, J. H.; Vemuganti, R., Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008, 13, 1813-26. (Pubitemid 351599735)
22. Pascual, G.; Glass, C. K., Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 2006, 17 (8), 321-7. (Pubitemid 44397567)
23. Pascual, G.; Fong, A. L.; Ogawa, S.; Gamliel, A.; Li, A. C.; Perissi, V.; Rose, D. W.; Willson, T. M.; Rosenfeld, M. G.; Glass, C. K., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437 (7059), 759-63. (Pubitemid 41486547)
24. Szanto, A.; Nagy, L., The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 2008, 213 (9-10), 789-803.
25. Desvergne, B.; Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20 (5), 649-88. (Pubitemid 30650602)
26. Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006, 58 (4), 726-41. (Pubitemid 44833742)
27. Vohl, M. C.; Lepage, P.; Gaudet, D.; Brewer, C. G.; Betard, C.; Perron, P.; Houde, G.; Cellier, C.; Faith, J. M.; Despres, J. P.; Morgan, K.; Hudson, T. J., Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000, 41 (6), 945-52. (Pubitemid 30434326)
28. Cheng, A. Y.; Leiter, L. A., PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. Diabetes Obes Metab 2008, 10 (9), 691-8.
29. Lefebvre, P.; Chinetti, G.; Fruchart, J. C.; Staels, B., Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116 (3), 571-80. (Pubitemid 43326861)
30. Adachi, M.; Kurotani, R.; Morimura, K.; Shah, Y.; Sanford, M.; Madison, B. B.; Gumucio, D. L.; Marin, H. E.; Peters, J. M.; Young, H. A.; Gonzalez, F. J., Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006, 55 (8), 1104-13. (Pubitemid 44085676)
31. Bedu, E.; Wahli, W.; Desvergne, B., Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin Ther Targets 2005, 9 (4), 861-73. (Pubitemid 41131684)
32. Bordet, R.; Gele, P.; Duriez, P.; Fruchart, J. C., PPARs: a new target for neuroprotection. J Neurol Neurosurg Psychiatry 2006, 77 (3), 285-7.
33. Seufert, S.; Coras, R.; Trankle, C.; Zlotos, D. P.; Blumcke, I.; Tatenhorst, L.; Heneka, M. T.; Hahnen, E., PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion. PPAR Res 2008, 2008, 513943.
34. Semple, R. K.; Chatterjee, V. K.; O'Rahilly, S., PPAR gamma and human metabolic disease. J Clin Invest 2006, 116 (3), 581-9. (Pubitemid 43326862)
35. Krishnan, A.; Nair, S. A.; Pillai, M. R., Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med 2007, 7 (6), 532-40. (Pubitemid 47618050)
36. Bongartz, T.; Coras, B.; Vogt, T.; Scholmerich, J.; Muller-Ladner, U., Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 2005, 44 (1), 126-9. (Pubitemid 40124345)
37. Jiang, Q.; Heneka, M.; Landreth, G. E., The role of peroxisome proliferatoractivated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008, 22 (1), 1-14. (Pubitemid 350243363)
38. Drew, P. D.; Xu, J.; Racke, M. K., PPAR-gamma: Therapeutic Potential for Multiple Sclerosis. PPAR Res 2008, 2008, 627463.
39. Thorp, J. M.; Waring, W. S., Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962, 194, 948-9.
40. Hellman, L.; Zumoff, B.; Kessler, G.; Kara, E.; Rubin, I. L.; Rosenfeld, R. S., Reduction of Serum Cholesterol and Lipids by Ethyl Chlorophenoxyisobutyrate. J Atheroscler Res 1963, 3, 454-66.
41. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270 (22), 12953-6.
42. Andreani, F.; Andrisano, R.; Andreani, A., New alpha-substituted arylthioacetic derivatives forming analogs of clofibrate. Farmaco Sci 1975, 30 (10), 847-58.
43. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y., Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2- phenylpropoxy)-benzyl] thiazolidine-2,4-dione (AL-321) and related compounds. Chem Pharm Bull (Tokyo) 1982, 30 (10), 3563-73. (Pubitemid 13210096)
44. Sohda, T.; Mizuno, K.; Imamiya, E.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y., Studies on antidiabetic agents. II. Synthesis of 5-[4-(1- methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull (Tokyo) 1982, 30 (10), 3580-600. (Pubitemid 13210097)
45. Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H., Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988, 37 (11), 1549-58.
46. Watkins, P. B.; Whitcomb, R. W., Hepatic dysfunction associated with troglitazone. N Engl J Med 1998, 338 (13), 916-7.
47. Smith, M. T., Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003, 16 (6), 679-87. (Pubitemid 36736599)
48. Oakes, N. D.; Kennedy, C. J.; Jenkins, A. B.; Laybutt, D. R.; Chisholm, D. J.; Kraegen, E. W., A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994, 43 (10), 1203-10. (Pubitemid 24361185)
49. Cantello, B. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L., [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 1994, 37 (23), 3977-85.
50. Sohda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung 1990, 40 (1), 37-42. (Pubitemid 20037527)
51. Pickavance, L. C.; Brand, C. L.; Wassermann, K.; Wilding, J. P., The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 2005, 144 (3), 308-16. (Pubitemid 40313676)
52. Askari, B.; Kanter, J. E.; Sherrid, A. M.; Golej, D. L.; Bender, A. T.; Liu, J.; Hsueh, W. A.; Beavo, J. A.; Coleman, R. A.; Bornfeldt, K. E., Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes 2007, 56 (4), 1143-52. (Pubitemid 46525070)
53. Nozawa, T.; Sugiura, S.; Nakajima, M.; Goto, A.; Yokoi, T.; Nezu, J.; Tsuji, A.; Tamai, I., Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 2004, 32 (3), 291-4. (Pubitemid 38263886)
54. Fryer, L. G.; Parbu-Patel, A.; Carling, D., The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002, 277 (28), 25226-32. (Pubitemid 34951829)
55. Tilley, D. G.; Nguyen, A. D.; Rockman, H. A., Troglitazone stimulates betaarrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochem Biophys Res Commun 2010, 396 (4), 921-6.
56. Biscetti, F.; Straface, G.; Arena, V.; Stigliano, E.; Pecorini, G.; Rizzo, P.; De Angelis, G.; Iuliano, L.; Ghirlanda, G.; Flex, A., Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Aktdependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc Diabetol 2009, 8, 49.
57. Gardner, O. S.; Shiau, C. W.; Chen, C. S.; Graves, L. M., Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. J Biol Chem 2005, 280 (11), 10109-18. (Pubitemid 40395863)
58. Reddy, J. K.; Goel, S. K.; Nemali, M. R.; Carrino, J. J.; Laffler, T. G.; Reddy, M. K.; Sperbeck, S. J.; Osumi, T.; Hashimoto, T.; Lalwani, N. D.; et al., Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc Natl Acad Sci U S A 1986, 83 (6), 1747-51. (Pubitemid 16018640)
59. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Cap, M.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweyko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T., Design and synthesis of N-[(4-methoxyphenoxy)carbonyl] -N-[[4-[2-(5-methyl-2- phenyl-4-oxazolyl)ethoxy] phenyl] methyl] glycine [Muraglitazar/BMS-298585] , a novel peroxisome proliferatoractivated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 2005, 48 (6), 2248-50. (Pubitemid 40396353)
60. Brown, P. J.; Smith-Oliver, T. A.; Charifson, P. S.; Tomkinson, N. C.; Fivush, A. M.; Sternbach, D. D.; Wade, L. E.; Orband-Miller, L.; Parks, D. J.; Blanchard, S. G.; Kliewer, S. A.; Lehmann, J. M.; Willson, T. M., Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chem Biol 1997, 4 (12), 909-18. (Pubitemid 28050375)
61. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliewer, S. A.; Willson, T. M., A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipidlowering activity. J Med Chem 1999, 42 (19), 3785-8. (Pubitemid 29453459)
62. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.; Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.; Bensch, W. R.; Barr, R. J.; Osborne, J.; Montrose-Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B., Design and synthesis of a potent and selective triazolone-based peroxisome proliferatoractivated receptor alpha agonist. J Med Chem 2003, 46 (24), 5121-4. (Pubitemid 37414181)
63. Nissen, S. E.; Nicholls, S. J.; Wolski, K.; Howey, D. C.; McErlean, E.; Wang, M. D.; Gomez, E. V.; Russo, J. M., Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007, 297 (12), 1362-73. (Pubitemid 46513237)
64. Sierra, M. L.; Beneton, V.; Boullay, A. B.; Boyer, T.; Brewster, A. G.; Donche, F.; Forest, M. C.; Fouchet, M. H.; Gellibert, F. J.; Grillot, D. A.; Lambert, M. H.; Laroze, A.; Le Grumelec, C.; Linget, J. M.; Montana, V. G.; Nguyen, V. L.; Nicodeme, E.; Patel, V.; Penfornis, A.; Pineau, O.; Pohin, D.; Potvain, F.; Poulain, G.; Ruault, C. B.; Saunders, M.; Toum, J.; Xu, H. E.; Xu, R. X.; Pianetti, P. M., Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem 2007, 50 (4), 685-95. (Pubitemid 46332981)
65. Billin, A. N., PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs 2008, 17 (10), 1465-71.
66. Li, J.; Kennedy, L. J.; Shi, Y.; Tao, S.; Ye, X. Y.; Chen, S. Y.; Wang, Y.; Hernandez, A. S.; Wang, W.; Devasthale, P. V.; Chen, S.; Lai, Z.; Zhang, H.; Wu, S.; Smirk, R. A.; Bolton, S. A.; Ryono, D. E.; Lim, N. K.; Chen, B. C.; Locke, K. T.; O'Malley, K. M.; Zhang, L.; Srivastava, R. A.; Miao, B.; Meyers, D. S.; Monshizadegan, H.; Search, D.; Grimm, D.; Zhang, R.; Harrity, T.; Kunselman, L. K.; Cap, M.; Kadiyala, P.; Hosagrahara, V.; Xu, C.; Li, Y. X.; Muckelbauer, J. K.; Chang, C.; An, Y.; Krystek, S. R.; Blanar, M. A.; Zahler, R.; Mukherjee, R.; Cheng, P. T.; Tino, J. A., Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarb onyl)amino)acetic acid (BMS-687453). J Med Chem 2010, 53 (7), 2854-64.
67. Burdick, A. D.; Kim, D. J.; Peraza, M. A.; Gonzalez, F. J.; Peters, J. M., The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal 2006, 18 (1), 9-20. (Pubitemid 41415710)
68. Shearer, B. G.; Wiethe, R. W.; Ashe, A.; Billin, A. N.; Way, J. M.; Stanley, T. B.; Wagner, C. D.; Xu, R. X.; Leesnitzer, L. M.; Merrihew, R. V.; Shearer, T. W.; Jeune, M. R.; Ulrich, J. C.; Willson, T. M., Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl] sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J Med Chem 2010, 53 (4), 1857-61.
69. Johnson, T. E.; Holloway, M. K.; Vogel, R.; Rutledge, S. J.; Perkins, J. J.; Rodan, G. A.; Schmidt, A., Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. J Steroid Biochem Mol Biol 1997, 63 (1-3), 1-8. (Pubitemid 28018130)
70. Riserus, U.; Sprecher, D.; Johnson, T.; Olson, E.; Hirschberg, S.; Liu, A.; Fang, Z.; Hegde, P.; Richards, D.; Sarov-Blat, L.; Strum, J. C.; Basu, S.; Cheeseman, J.; Fielding, B. A.; Humphreys, S. M.; Danoff, T.; Moore, N. R.; Murgatroyd, P.; O'Rahilly, S.; Sutton, P.; Willson, T.; Hassall, D.; Frayn, K. N.; Karpe, F., Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57 (2), 332-9.
71. http://clinicaltrials.gov/ct2/show/NCT01042769. [accessed September 16 2011].
72. Tesse, A.; Andriantsitohaina, R.; Ragot, T., PPARdelta Activity in Cardiovascular Diseases: A Potential Pharmacological Target. PPAR Res 2009, 2009, 745821.
73. Mogensen, J. P.; Jeppesen, L.; Bury, P. S.; Pettersson, I.; Fleckner, J.; Nehlin, J.; Frederiksen, K. S.; Albrektsen, T.; Din, N.; Mortensen, S. B.; Svensson, L. A.; Wassermann, K.; Wulff, E. M.; Ynddal, L.; Sauerberg, P., Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Bioorg Med Chem Lett 2003, 13 (2), 257-60. (Pubitemid 35441346)
74. Sauerberg, P.; Olsen, G. S.; Jeppesen, L.; Mogensen, J. P.; Pettersson, I.; Jeppesen, C. B.; Daugaard, J. R.; Galsgaard, E. D.; Ynddal, L.; Fleckner, J.; Panajotova, V.; Polivka, Z.; Pihera, P.; Havranek, M.; Wulff, E. M., Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo. J Med Chem 2007, 50 (7), 1495-503. (Pubitemid 46564371)
75. Epple, R.; Cow, C.; Xie, Y.; Azimioara, M.; Russo, R.; Wang, X.; Wityak, J.; Karanewsky, D. S.; Tuntland, T.; Nguyen-Tran, V. T.; Cuc Ngo, C.; Huang, D.; Saez, E.; Spalding, T.; Gerken, A.; Iskandar, M.; Seidel, H. M.; Tian, S. S., Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists. J Med Chem 2010, 53 (1), 77-105.
76. Ibrahimi, A.; Teboul, L.; Gaillard, D.; Amri, E. Z.; Ailhaud, G.; Young, P.; Cawthorne, M. A.; Grimaldi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 1994, 46 (6), 1070-6.
77. Reginato, M. J.; Bailey, S. T.; Krakow, S. L.; Minami, C.; Ishii, S.; Tanaka, H.; Lazar, M. A., A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem 1998, 273 (49), 32679-84. (Pubitemid 28557651)
78. Parks, D. J.; Tomkinson, N. C.; Villeneuve, M. S.; Blanchard, S. G.; Willson, T. M., Differential activity of rosiglitazone enantiomers at PPAR gamma. Bioorg Med Chem Lett 1998, 8 (24), 3657-8. (Pubitemid 29012595)
79. Haigh, D.; Allen, G.; Birrell, H. C.; Buckle, D. R.; Cantello, B. C.; Eggleston, D. S.; Haltiwanger, R. C.; Holder, J. C.; Lister, C. A.; Pinto, I. L.; Rami, H. K.; Sime, J. T.; Smith, S. A.; Sweeney, J. D., Nonthiazolidinedione antihyperglyciemic agents. Part 3: The effects of stereochemistry on the potency of alpha-methoxy-beta-phenylpropanoic acids. Bioorg Med Chem 1999, 7 (5), 821-30. (Pubitemid 29238077)
80. Ljung, B.; Bamberg, K.; Dahllof, B.; Kjellstedt, A.; Oakes, N. D.; Ostling, J.; Svensson, L.; Camejo, G., AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 2002, 43 (11), 1855-63. (Pubitemid 35315803)
81. Brown, K. K.; Henke, B. R.; Blanchard, S. G.; Cobb, J. E.; Mook, R.; Kaldor, I.; Kliewer, S. A.; Lehmann, J. M.; Lenhard, J. M.; Harrington, W. W.; Novak, P. J.; Faison, W.; Binz, J. G.; Hashim, M. A.; Oliver, W. O.; Brown, H. R.; Parks, D. J.; Plunket, K. D.; Tong, W. Q.; Menius, J. A.; Adkison, K.; Noble, S. A.; Willson, T. M., A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999, 48 (7), 1415-24. (Pubitemid 29297304)
82. McHutchison, J.; Goodman, Z.; Patel, K.; Makhlouf, H.; Rodriguez-Torres, M.; Shiffman, M.; Rockey, D.; Husa, P.; Chuang, W. L.; Levine, R.; Jonas, M.; Theodore, D.; Brigandi, R.; Webster, A.; Schultz, M.; Watson, H.; Stancil, B.; Gardner, S., Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 2010, 138 (4), 1365-73, 1373 e1-2.
83. Cheatham, W. W., Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 2010, 91 (1), 262S-266S.
84. Ahn, J. H.; Shin, M. S.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Jung, W. H.; Yang, S. D.; Kim, S. J.; Woo, J. R.; Lee, J. H.; Cheon, H. G.; Kim, S. S., Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. J Med Chem 2006, 49 (15), 4781-4. (Pubitemid 44162706)
85. Lehmann, J. M.; Lenhard, J. M.; Oliver, B. B.; Ringold, G. M.; Kliewer, S. A., Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272 (6), 3406-10.
86. Jaradat, M. S.; Wongsud, B.; Phornchirasilp, S.; Rangwala, S. M.; Shams, G.; Sutton, M.; Romstedt, K. J.; Noonan, D. J.; Feller, D. R., Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001, 62 (12), 1587-95. (Pubitemid 34033644)
87. Kojo, H.; Fukagawa, M.; Tajima, K.; Suzuki, A.; Fujimura, T.; Aramori, I.; Hayashi, K.; Nishimura, S., Evaluation of human peroxisome proliferatoractivated receptor (PPAR) subtype selectivity of a variety of antiinflammatory drugs based on a novel assay for PPAR delta(beta). J Pharmacol Sci 2003, 93 (3), 347-55. (Pubitemid 37521357)
88. Felts, A. S.; Siegel, B. S.; Young, S. M.; Moth, C. W.; Lybrand, T. P.; Dannenberg, A. J.; Marnett, L. J.; Subbaramaiah, K., Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. J Med Chem 2008, 51 (16), 4911-9.
89. Liu, Q.; Zhang, Y. Y.; Lu, H. L.; Li, Q. Y.; Zhou, C. H.; Wang, M. W., Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists. Acta Pharmacol Sin 2007, 28 (12), 2033-9. (Pubitemid 351972341)
90. Shearer, B. G.; Billin, A. N., The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 2007, 1771 (8), 1082-93. (Pubitemid 47202036)
91. Suh, Y. G.; Kim, N. J.; Koo, B. W.; Lee, K. O.; Moon, S. H.; Shin, D. H.; Jung, J. W.; Paek, S. M.; Chang, D. J.; Li, F.; Kang, H. J.; Le, T. V.; Chae, Y. N.; Shin, C. Y.; Kim, M. K.; Lim, J. I.; Ryu, J. S.; Park, H. J., Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. J Med Chem 2008, 51 (20), 6318-33.
92. Fievet, C.; Fruchart, J. C.; Staels, B., PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006, 6 (6), 606-14. (Pubitemid 44660945)
93. Matin, A.; Gavande, N.; Kim, M. S.; Yang, N. X.; Salam, N. K.; Hanrahan, J. R.; Roubin, R. H.; Hibbs, D. E., 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. J Med Chem 2009, 52 (21), 6835-50.
94. Fracchiolla, G.; Laghezza, A.; Piemontese, L.; Tortorella, P.; Mazza, F.; Montanari, R.; Pochetti, G.; Lavecchia, A.; Novellino, E.; Pierno, S.; Conte Camerino, D.; Loiodice, F., New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. J Med Chem 2009, 52 (20), 6382-93.
95. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J. C.; Staels, B., Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007, 1771 (8), 1065-81. (Pubitemid 47208546)
96. Montanari, R.; Saccoccia, F.; Scotti, E.; Crestani, M.; Godio, C.; Gilardi, F.; Loiodice, F.; Fracchiolla, G.; Laghezza, A.; Tortorella, P.; Lavecchia, A.; Novellino, E.; Mazza, F.; Aschi, M.; Pochetti, G., Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. In J Med Chem, 2008/12/05 ed.; 2008; Vol. 51, pp 7768-76.
97. Henke, B. R., Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem 2004, 47 (17), 4118-27. (Pubitemid 39045415)
98. Liu, K. G.; Lambert, M. H.; Leesnitzer, L. M.; Oliver, W., Jr.; Ott, R. J.; Plunket, K. D.; Stuart, L. W.; Brown, P. J.; Willson, T. M.; Sternbach, D. D., Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis. Bioorg Med Chem Lett 2001, 11 (22), 2959-62. (Pubitemid 33000105)
99. Gonzalez, I. C.; Lamar, J.; Iradier, F.; Xu, Y.; Winneroski, L. L.; York, J.; Yumibe, N.; Zink, R.; Montrose-Rafizadeh, C.; Etgen, G. J.; Broderick, C. L.; Oldham, B. A.; Mantlo, N., Design and synthesis of a novel class of dual PPARgamma/delta agonists. Bioorg Med Chem Lett 2007, 17 (4), 1052-5. (Pubitemid 46177609)
100. Tenenbaum, A.; Motro, M.; Fisman, E. Z., Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4, 14.
101. Ramachandran, U.; Kumar, R.; Mittal, A., Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. Mini Rev Med Chem 2006, 6 (5), 563-73. (Pubitemid 43731183)
102. Etgen, G. J.; Oldham, B. A.; Johnson, W. T.; Broderick, C. L.; Montrose, C. R.; Brozinick, J. T.; Misener, E. A.; Bean, J. S.; Bensch, W. R.; Brooks, D. A.; Shuker, A. J.; Rito, C. J.; McCarthy, J. R.; Ardecky, R. J.; Tyhonas, J. S.; Dana, S. L.; Bilakovics, J. M.; Paterniti, J. R., Jr.; Ogilvie, K. M.; Liu, S.; Kauffman, R. F., A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002, 51 (4), 1083-7. (Pubitemid 34438353)
103. Glover, B. N.; Jones, L. A.; Johnson, B. S.; Millar, A.; Osterhout, M. H.; Xie, S., Effects of Various Bases on Acid-Catalyzed Amination of 2-Chloro-5-ethylpyrimidine: Synthesis of PPARpan Agonist GW693085. J Org Chem 2010, 75 (11), 3904-7.
104. Shang, Y.; Hu, X.; DiRenzo, J.; Lazar, M. A.; Brown, M., Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103 (6), 843-52.
105. Choi, J. H.; Banks, A. S.; Estall, J. L.; Kajimura, S.; Bostrom, P.; Laznik, D.; Ruas, J. L.; Chalmers, M. J.; Kamenecka, T. M.; Bluher, M.; Griffin, P. R.; Spiegelman, B. M., Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466 (7305), 451-6.
106. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M., A peroxisome proliferatoractivated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A 1999, 96 (11), 6102-6. (Pubitemid 29256626)
107. Larsen, P. J.; Lykkegaard, K.; Larsen, L. K.; Fleckner, J.; Sauerberg, P.; Wassermann, K.; Wulff, E. M., Dissociation of antihyperglyciemic and adverse effects of partial perioxisome proliferator-activated receptor (PPARgamma) agonist balaglitazone. Eur J Pharmacol 2008, 596 (1-3), 173-9.
108. Doshi, L. S.; Brahma, M. K.; Bahirat, U. A.; Dixit, A. V.; Nemmani, K. V., Discovery and development of selective PPARgamma modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs 2010, 19 (4), 489-512.
109. Henriksen, K.; Byrjalsen, I.; Qvist, P.; Beck-Nielsen, H.; Hansen, G.; Riis, B. J.; Perrild, H.; Svendsen, O. L.; Gram, J.; Karsdal, M. A.; Christiansen, C., Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallelgroup study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011, 27 (4), 392-401.
110. Motani, A.; Wang, Z.; Weiszmann, J.; McGee, L. R.; Lee, G.; Liu, Q.; Staunton, J.; Fang, Z.; Fuentes, H.; Lindstrom, M.; Liu, J.; Biermann, D. H.; Jaen, J.; Walker, N. P.; Learned, R. M.; Chen, J. L.; Li, Y., INT131: a selective modulator of PPAR gamma. J Mol Biol 2009, 386 (5), 1301-11.
111. Higgins, L. S.; Depaoli, A. M., Selective peroxisome proliferator- activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010, 91 (1), 267S-272S.
112. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M., Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 2001, 98 (24), 13919-24. (Pubitemid 33115999)
113. Loiodice, F.; Pochetti, G., Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods. Curr Top Med Chem 2011, 11 (7), 819-39.
114. Cronet, P.; Petersen, J. F.; Folmer, R.; Blomberg, N.; Sjoblom, K.; Karlsson, U.; Lindstedt, E. L.; Bamberg, K., Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9 (8), 699-706. (Pubitemid 32772892)
115. Benardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Boehringer, M.; Grether, U.; Hilpert, H.; Kuhn, B.; Marki, H. P.; Meyer, M.; Puntener, K.; Raab, S.;
116. Artis, D. R.; Lin, J. J.; Zhang, C.; Wang, W.; Mehra, U.; Perreault, M.; Erbe, D.; Krupka, H. I.; England, B. P.; Arnold, J.; Plotnikov, A. N.; Marimuthu, A.; Nguyen, H.; Will, S.; Signaevsky, M.; Kral, J.; Cantwell, J.; Settachatgull, C.; Yan, D. S.; Fong, D.; Oh, A.; Shi, S.; Womack, P.; Powell, B.; Habets, G.; West, B. L.; Zhang, K. Y.; Milburn, M. V.; Vlasuk, G. P.; Hirth, K. P.; Nolop, K.; Bollag, G.; Ibrahim, P. N.; Tobin, J. F., Scaffoldbased discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A 2009, 106 (1), 262-7.
117. Oyama, T.; Toyota, K.; Waku, T.; Hirakawa, Y.; Nagasawa, N.; Kasuga, J. I.; Hashimoto, Y.; Miyachi, H.; Morikawa, K., Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta Crystallogr D Biol Crystallogr 2009, 65 (Pt 8), 786-95.
118. Kasuga, J.; Yamasaki, D.; Araya, Y.; Nakagawa, A.; Makishima, M.; Doi, T.; Hashimoto, Y.; Miyachi, H., Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. Bioorg Med Chem 2006, 14 (24), 8405-14. (Pubitemid 44755267)
119. Lyne, P. D., Structure-based virtual screening: an overview. Drug Discov Today 2002, 7 (20), 1047-55.
120. Polgar, T. The role of structure based virtual screening in the early phase of drug discovery. Acta Pharm Hung 2007, 77 (4), 223-34.
121. Sheridan, R. P.; Kearsley, S. K., Why do we need so many chemical similarity search methods? Drug Discov Today 2002, 7 (17), 903-11.
122. Yang, Y.; Carta, G.; Peters, M. B.; Price, T.; O'Boyle, N.; Knox, A. J. S.; Fayne, D.; Williams, D. C.; Megan, M. J.; Lloyd, D. G., 'tieredScreen'- Layered Virtual Screening Tool for the Identification of Novel Estrogen Receptor Alpha Modulators. Molecular Informatics 2010, (29), 421-430.
123. Scarsi, M.; Podvinec, M.; Roth, A.; Hug, H.; Kersten, S.; Albrecht, H.; Schwede, T.; Meyer, U. A.; Rucker, C., Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol 2007, 71 (2), 398-406. (Pubitemid 46147906)
124. Rucker, C.; Scarsi, M.; Meringer, M., 2D QSAR of PPARgamma agonist binding and transactivation. Bioorg Med Chem 2006, 14 (15), 5178-95. (Pubitemid 43903265)
125. Markt, P.; Schuster, D.; Kirchmair, J.; Laggner, C.; Langer, T., Pharmacophore modeling and parallel screening for PPAR ligands. J Comput Aided Mol Des 2007, 21 (10-11), 575-90. (Pubitemid 350238548)
126. Steindl, T.; Langer, T., Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening. J Chem Inf Comput Sci 2004, 44 (5), 1849-56.
127. Markt, P.; Petersen, R. K.; Flindt, E. N.; Kristiansen, K.; Kirchmair, J.; Spitzer, G.; Distinto, S.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T., Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. J Med Chem 2008, 51 (20), 6303-17.
128. Sundriyal, S.; Viswanad, B.; Ramarao, P.; Chakraborti, A. K.; Bharatam, P. V., New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. Bioorg Med Chem Lett 2008, 18 (18), 4959-62.
129. Kulkarni, S. S.; Gediya, L. K.; Kulkarni, V. M., Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. Bioorg Med Chem 1999, 7 (7), 1475-85. (Pubitemid 29292388)
130. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V., Ligand binding and co-activator assembly of the peroxisome proliferatoractivated receptor-gamma. Nature 1998, 395 (6698), 137-43. (Pubitemid 28425645)
131. Catalyst, 4.10; Accelrys Inc.: San Diego, CA, USA.
132. Tanrikulu, Y.; Rau, O.; Schwarz, O.; Proschak, E.; Siems, K.; Muller-Kuhrt, L.; Schubert-Zsilavecz, M.; Schneider, G., Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists. Chembiochem 2009, 10 (1), 75-8.
133. Salam, N. K.; Huang, T. H.; Kota, B. P.; Kim, M. S.; Li, Y.; Hibbs, D. E., Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 2008, 71 (1), 57-70.
134. Derksen, S.; Rau, O.; Schneider, P.; Schubert-Zsilavecz, M.; Schneider, G., Virtual screening for PPAR modulators using a probabilistic neural network. ChemMedChem 2006, 1 (12), 1346-50.
135. Vidovic, D.; Busby, S. A.; Griffin, P. R.; Schurer, S. C., A combined ligandand structure-based virtual screening protocol identifies submicromolar PPARgamma partial agonists. ChemMedChem 2011, 6 (1), 94-103.
136. Guasch, L.; Sala, E.; Valls, C.; Blay, M.; Mulero, M.; Arola, L.; Pujadas, G.; Garcia-Vallve, S., Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des 25 (8), 717-28.